BLUE JET HEALTHCARE

Investor Presentation

Q4 & FY26



Disclaimer

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceutical and chemical industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Blue Jet Healthcare Ltd.

BLUE JET HEALTHCARE

Table of **Content**



1 Q4 & FY26 Financials

2 Company at a Glance

3 Contrast Media Intermediates

4 High Intensity Sweeteners

5 Pharma Intermediates & API

6 R&D Capabilities

7 Growth Strategy

8 Management and Board of Directors



1

Q4 & FY26 Financials

Q4 FY26 vs Q3 FY26 (QoQ) Earnings Highlights

Financial Highlights

- ✓ **Revenue from Operation in Q4 FY26** is **Rs. 2,347 mn, EBITDA Rs. 713 mn (30% Margin)** and **PAT Rs. 643 mn (27% Margin)**
- ✓ **Revenue from Operation** in **Q3 FY26** was **Rs. 1,924 mn, EBITDA Rs. 469 mn (24% Margin)** and **PAT Rs. 402 mn (21% Margin)**
- ✓ **QoQ comparison, Revenue from operations increased** by **22%, EBITDA increased** by **52% [Rs 244 mn] and PAT increased** by **60% [Rs 241 mn]** during **Q4 FY26.**
- ✓ **The increase in Revenue from Operations** during current quarter is due to higher sales of Advance Contrast media.
- ✓ **Gross Margin** for **Q4 FY26** was at **56%, higher compared to Q3 FY26 (52%),** mainly driven by favourable product mix and higher sales of Contrast media intermediates.
- ✓ **EBIDTA Margin** stands at **30%** for the quarter, higher due improved gross margin . Lower employee cost and benefit of higher sales volume & operating leverage.



Q4 FY26 vs Q4 FY25 (YoY) Earnings Highlights

Financial Highlights

- ✓ **Revenue from Operation** in **Q4 FY26** is **Rs.2,347 mn, EBITDA Rs. 713 mn (30% Margin)** and **PAT Rs. 643 mn (27% Margin)**
- ✓ **Revenue from Operation** in **Q4 FY25** was **Rs. 3,404 mn, EBITDA Rs. 1,400 mn (41% Margin)** and **PAT Rs. 1,101 mn (32% Margin)**
- ✓ **YoY comparison**, **Revenue from operations decreased** by **31%, EBITDA decreased** by **49% [Rs 687 mn]** and **PAT decreased** by **42% [Rs. 458 mn]** during **Q4 FY26,** due to negligible sales of one of our molecules in the PI vertical. The revenue performance reflects timing-related order phasing in select PI accounts, along with customer-side inventory normalization.
- ✓ **We maintain strong visibility** on the underlying demand and expect normalization to reflect in upcoming quarters
- ✓ **Gross Margin** for **Q4 FY26** was at **56% Vs 55% in Q4 FY25,** and was stable owing to strong growth reflected in Contrast media Business



FY26 Earnings Highlights

Financial Highlights

- ✓ **Revenue from Operation** for **FY26** is **Rs. 9,473 mn, EBITDA Rs. 2,941 mn (31% Margin)** and **PAT Rs. 2,478 mn (26% Margin)**
- ✓ **Revenue from Operation** for **FY25 was Rs 10,300 mn, EBITDA Rs. 3,777 mn (37% Margin)** and **PAT Rs. 3,052 mn (30% Margin)**
- ✓ **YoY comparison,** Revenue from operations **decreased by 8%, EBITDA decreased by 22% [Rs. 836 mn]** and **PAT decreased by 19% [Rs. 574 mn]** during FY26. The decline in Revenue from Operations in FY26 is primarily due to **lower sales in the PI & API segment; however, robust growth in Contrast Media partially offset the decline.**
- ✓ **EBITDA Margin decreased from 37% to 31%, primarily due to increase in certain operating costs coupled with lower sales volumes.**
- ✓ **Gross Margin** for **FY26 is at 54% Vs FY25 at 55%. The margins have remained stable.**
- ✓ **Other income increased in FY26 to Rs. ~687 mn from Rs. ~463 mn,** mainly driven by **foreign exchange gains .**



FY26 Earnings Highlights

Business Updates


- ✓ **Vizag Project ground-breaking ceremony completed** and project activities have commenced
- ✓ **R&D Centre Hyderabad civil construction at Hyderabad commenced** – expected to be completed on or before **September 2026 – Hiring of Key Resources Initited**
- ✓ **Pharma Intermediate [PI] de-stocking and inventory normalization completed by customer ; Robust revenues expected backed by orders from this segment in the coming quarters**
- ✓ **Received trial orders in Advanced Contrast Media** from a new Japanese customer




Q4 FY26 Vs Q4 FY25 Financial Performance – Key Metrics

Revenue from Operations** – Growth Trends


(Rs Mn)




EBITDA Profile



PAT Profile







- *Others include spent oils and industrial mix solvents and R&D services .
- **Excludes Other Operating Revenue.


FY26 Vs FY25 Financial Performance – Key Metrics


Revenue from Operations** – Growth Trends

(Rs Mn)









- *Others include spent oils and industrial mix solvents and R&D
- **Excludes Other Operating Revenue


Profit and Loss Statement

Particulars (Rs. Mn)	Q4 FY26	Q3 FY26	QoQ	Q4 FY25	YoY	FY26	FY25	YoY
Revenue from Operations	**2,347**	**1,924**	**22.0%**	**3,404**	**-31.1%**	**9,473**	**10,300**	**-8.0%**
Cost Of Goods Sold	1022	928		1,535		4,358	4,612	
Gross Profit	**1,325**	**996**	**33.0%**	**1,870**	**-29.2%**	**5,115**	**5,688**	**-10.1%**
Gross Margin	*56.4%*	*51.7%*		*54.9%*		*54.0%*	*55.2%*	
Employee benefits expenses	185	191		160		735	610	
Other expenses	427	336		310		1,439	1,300	
Total Expenses	1,634	1,455		2,005		6,532	6,523	
EBITDA	**713**	**469**	**52.0%**	**1,400**	**-49.1%**	**2,941**	**3,777**	**-22.1%**
EBITDA Margin	*30.4%*	*24.4%*		*41.1%*		*31.0%*	*36.7%*	
Depreciation and amortization	65	60		49		240	178	
PBIT	**877**	**541**	**62.1%**	**1,472**	**-40.4%**	**3,388**	**4,062**	**-16.6%**
Exceptional Items	-	-		-		-	-	
Finance costs	6	3		0		62	1	
Other Income	229	132		122		687	463	
PBT	**871**	**538**	**62.1%**	**1,472**	**-40.8%**	**3,325**	**4,061**	**-18.1%**
Tax Expense	228	136		371		847	1,009	
PAT	**643**	**402**	**60.2%**	**1,101**	**-41.6%**	**2,478**	**3,052**	**-18.8%**
PAT Margin	*27.4%*	*20.9%*		*32.3%*		*26.2%*	*29.6%*	


Financial Performance over the years – Key Metrics

Revenue from Operations** – Growth Trends


(Rs Mn)



EBITDA Profile



PAT Profile



- *Others include spent oils, Industrial mix solvents and R&D
- **Excludes Other Operating Revenue

Financials for the last five years

Summary Statement of Profit and Loss


Particulars (Rs. Mn)	FY21	FY22	FY23	FY24	FY25	FY26
Revenue from Operations	4,989	6,835	7,210	7,116	10,300	9,473
Other Income	89	194	240	289	463	687
Total Revenue	**5,078**	**7,029**	**7,449**	**7,404**	**10,762**	**10,160**
Cost of Materials consumed	1,695	2,875	3,360	3,144	4,612	4,358
Employee benefits expenses	290	330	419	532	610	735
Finance costs	53	33	14	2	1	62
Depreciation and amortization	197	221	251	281	178	240
Other expenses	945	1,137	1,240	1,148	1,300	1,439
Total Expenses	**3,178**	**4,597**	**5,283**	**5,106**	**6,701**	**6,834**
Exceptional Items	(53)	-	-	(97)	-	-
PBT	**1,847**	**2,432**	**2,166**	**2,200**	**4,061**	**3,325**
Tax Expense	489	616	566	563	1,009	847
PAT	**1,358**	**1,816**	**1,600**	**1,637**	**3,052**	**2,478**

Summary Statement of Assets and Liabilities

Particulars (Rs. Mn)	FY21	FY22	FY23	FY24	FY25	FY26
I. Assets						
Property, plant and equipment	1,188	1,185	1,282	1,491	2,596	2,529
Other non-current assets	275	466	688	2,041	1,519	4,312
Total non-current assets	**1,463**	**1,651**	**1,970**	**3,532**	**4,116**	**6,841**
Inventories	1,177	1,050	1,257	1,298	2,639	1,874
Trade receivables	1,440	2,274	2,394	1,769	3,495	3,390
Investments (Current)	368	938	1,893	2,355	1,867	2,267
Cash and cash equivalents	611	754	654	410	330	609
Other current assets	304	467	453	1,224	1,728	1,430
Total current assets	**3,900**	**5,483**	**6,651**	**7,056**	**10,059**	**9,570**
Total assets	**5,363**	**7.134**	**8.621**	**10,588**	**14,175**	**16,412**
II. Equity and liabilities						
Total equity	**3,398**	**5,215**	**6,815**	**8,452**	**11,331**	**13,599**
Borrowings	287	-	-	-	-	-
Other non-current liabilities	47	173	67	77	285	538
Total non-current liabilities	**334**	**173**	**67**	**77**	**285**	**538**
Current borrowings	229	-	-	-	-	-
Trade payables	595	565	538	303	891	569
Other current liabilities	807	1,180	1,201	1,757	1,669	1,706
Total current liabilities	**1,631**	**1,745**	**1,739**	**2,060**	**2,559**	**2,275**
Total liabilities	**1,965**	**1,918**	**1,806**	**2,136**	**2,844**	**2,813**
Total equity and liabilities	**5,363**	**7,134**	**8,621**	**10,588**	**14,175**	**16,412**

Shareholder Information

Shareholding as on 31st March 2026



Share Information as on 31st March 2026

NSE Ticker	BLUEJET
BSE Ticker	544009
Market Cap (INR Cr) (BSE)	5,676
% free-float	20.2%
Free-float market cap (INR Cr)	1,146
Cash & Cash Equivalents + Treasury Investment (INR Mn) (As on 31st March 2026)	3,619
Shares Outstanding	17,34,65,425
3M ADTV (Shares)*	7,54,980
3M ADTV (INR Cr)*	29.8
Industry	Pharmaceuticals


*Source: NSE & BSE
ADTV (Shares): Average Daily Traded Volume
ADTV (INR Cr): Average Daily Traded Value



2

Company at a Glance

Our Journey


1968
Established Jet Chemicals Private Limited with Shahad facility (Unit I)
1970
Began manufacturing high-intensity sweeteners - saccharin and its salts
2000
Entered the X-ray contrast media sector, with a basic building block (5- NIPA)
2002
Commenced manufacturing of pharma intermediates and API
2003
Established Blue Circle Organics Private Limited (at Unit-II, Ambernath facility)
2017
Commenced semi-automated manufacturing block for contrast media intermediate business
2019
Received USFDA Establishment Inspection Report of Blue Circle Organics Private Limited for Unit II
Merger between Blue Circle Organics and Jet Chemicals to form Blue Jet Healthcare Private Limited
2020
Acquisition of brownfield site in Mahad (Unit III) on a leasehold basis
2021
Acquisition of greenfield site in Ambernath (Unit IV) on a leasehold basis
2025
Supply of Pharmaceutical Intermediate to an innovator
Company successfully commissioned Plant 6 at Ambernath
2026
Acquisition of land near Vizag and groundbreaking of the project

Who we are

A **specialty pharmaceutical** and

healthcare ingredient and **intermediate**

company, offering **niche products** with

an approach of **“Collaboration,**

Development, Manufacturing” to

CDMO business.



Blue Jet Healthcare at a glance

Key metrics

51[1]
Commercialized product portfolio (FY26)

1,175.60 KL
reaction capacity across 3 facilities (FY26)

INR 9,473.2 mn
Revenue (FY26) (13.7% FY21-26 CAGR)

INR 2,940.99 mn
EBITDA (FY26) (31.0% margin)

24.9%
ROCE (FY26)

19.9%
ROE (FY26)

3.75x
Fixed Asset Turnover (FY26)

INR 3,619 mn
Cash and Cash Equivalents + Treasury Investments (as of 31st March 2026)

Business Overview

Three product categories: **Contrast Media Intermediates, High Intensity Sweeteners, and Pharma Intermediates & Active Pharmaceutical Ingredients ("API")**

Specialised chemistry capabilities; with dedicated R&D laboratories




Long-standing relationships and **multi-year contracts** with multi-national customers

Manufacturing facilities with regulatory accreditations

1. Includes 19, 4, and 28 commercialized products for contrast media, high intensity sweeteners, and pharma intermediates and APIs respectively

Source: Company Information

Overview of our Product Categories

	Contrast Media Intermediates	High Intensity Sweeteners	Pharma Intermediates & APIs
Overview	■ Contrast media are agents used in medical imaging to enhance the visibility of body tissues ■ Company supplies critical starting intermediate and several advanced intermediates	■ High-intensity sweetener business involves development, manufacture and marketing of saccharin and its salts	■ Collaboration with innovator pharmaceutical companies and multi-national generic companies ■ Provides intermediates that serve as pharmaceutical building blocks for APIs in chronic therapeutic areas
End uses	 *X-ray & CT Scan*  *MRI Scan*	■ Table-top sweeteners, oral care products, beverages (primarily soft-drinks), confectionary products, pharmaceutical products, food supplements, and animal feeds	■ Chronic therapeutic areas such as cardiovascular system ("CVS"), central nervous system ("CNS"), oncology etc
# of commercialized products (FY26)	**19**	**4**	**28**
Revenue contribution (FY26)	 52.50%	 13.90%	 31.60%
Client relationships	■ Top 4 players accounts for **~75%** global market share[1] ■ **4–27** years of relationship with the **3 of the largest manufacturers .**	■ **Offers high-intensity sweeteners to over 300** customers globally ■ **Marquee customers – in FMCG and Agro chemical Space**	■ Markets predominantly in **regulated markets** ■ Over **56** customers globally of which **40** in India

Note: [1] In each of MAT June 2019, 2020, 2021, 2022 and 2023
Source: Company information, IQVIA report dated October 9, 2023 ("Industry Report")



3

Contrast Media Intermediates

Overview of Contrast Media and its growth drivers

What is contrast media?

- Chemical agents that **enhances the contrast of an imaging modality** in diagnostic imaging, thereby **aiding diagnosis of diseases**
- Once inside the human body, selectively and temporarily taken up by different body tissues
- **Enhance the images, leading to better visualizations of the tissues and organs**

Types of contrast media

- **X-ray / Computed Tomography (CT) contrast agents:** Iodine-based contrast media agents
- **Magnetic Resonance Imaging (MRI) contrast agents:** Gadolinium-based agents
- **Ultrasound (USG) agents:** Stabilized microbubble-based contrast media agents

Growth drivers for contrast media

Growing population and changing demographics
(65 yrs.+) estimated to increase from 6.9% of the total world population in 2000 to 10.4% by 2025[1]

Growing prevalence of lifestyle diseases
Such as diabetes, physical inactivity, obesity, etc.

Increased convenience
Through online booking and reporting

Rising healthcare expenditure
Global health expenditure grew at 3.9% CAGR from 2000–17


Focus on early diagnostics
Driven by advancement in diagnostic technologies and growing public awareness

Increasing demand for preventive healthcare
Driven by increased awareness and rising curative costs


Note: [1] World Bank national account data
Source: Industry Report

The global Contrast Media industry is highly concentrated


Global Medical Imaging Market (USD Bn)



Global Contrast Media Formulation Market Revenue (USD Bn)




Revenue Share of Contrast Agent type, 2024




- Collectively **hold ~75% of the global sales of** contrast media formulations[1]
- **Highly concentrated** and **dominated by multi-national corporations**
- Either **forward integrated** (have equipment manufacturing) or **long-standing relationships with manufacturers**

Global Contrast Media Formulations Market, Market Share of Top Companies, 2024



Global Contrast Media Intermediates Market Revenue (USD Mn)



1. June 2019, 2020, 2021, 2022 and 2023

Source: F&S Report

High entry barriers for key intermediates' vendors

Characteristics of the Contrast Media market

- **Strict internal standards for product impurity / features profile**
- **Stickiness of relationship**
- **Long-term supply contracts**


Blue Jet's positioning

- ✓ More than **two decades of experience**
- ✓ **75%+ of exports** of a selected contrast media intermediate **(5-Amino-N,N'-bis (2,3-dihydroxypropyl) isophthalamide)** from India[1]
- ✓ Strategically **focused on complex chemistry** categories

- ✓ Regularly supplying **key starting intermediate** as the building block
- ✓ Several **functionally critical advanced intermediates**
- ✓ **4 to 27** years with 3 of the largest contrast media manufacturers in the world, directly

- ✓ **Medium to long term supply contracts** with customers
- ✓ **~70% of total sales** backed by **contracted** sales volumes[2]
- ✓ **Products qualified, approved and validated**

Contrast Media Intermediate product category performance



Source: Company information

Note: [1] In each of the Financial Years 2020, 2021 and 2022; 2 For Financial Years 2021, 2022, 2023 and three months ended 1Q 2023
Source: Industry Report

Continue to forward integrate into more advanced intermediates for Contrast Media

Strong product development and process **optimization capabilities** underpinned by **in-house R&D capabilities**

Focus on molecules with **customer interest** and **strategy** in either **outsourcing or alternate sourcing** the next stage of advanced intermediates

Key starting intermediate as building block in 2000 to **19 additional advanced intermediates** as of FY26

Further **improving chemistry** capabilities in close **synergy** with our customers (**4 to 27** years with 3 of top 4 players directly)

Key benefits

Capture **larger wallet share** with existing customers

Higher realization and **profitability** per unit

Potential of **moving up the value chain**



4

High Intensity Sweeteners

Blue Jet’s positioning in High Intensity Sweetener

Blue Jet's positioning

Products

- Adherence **to strict internal standards** to ensure **consistency in quality, performance, taste, and impurity profile**
- **Multiple products** and **applications** enabling to cater a **diverse customer base**


Compliance, GMP, supply chain reliability

- **Have received US-FDA inspection report**
- Semi-automated manufacturing facility
- **Strong product development and process optimization capabilities**

Customers

- Offers high-intensity sweeteners to over **300 customers globally**
- Focus on **marquee customers** across various sub-sectors
  - Table-top sweeteners, oral care products, beverages (primarily soft-drinks), confectionary products, pharmaceutical products, food supplements, and animal feeds


High Intensity Sweeteners product category performance




Sources: Company information

Global High Intensity Sweeteners Market

Global Artificial Sweeetener Market Revenue (USD Mn)




Global High-intensity Sweetneer Market, Revenue share by segments, 2024




Global Sucralose Market Revenue (USD Mn)

CAGR, 2019-2024 - 5.2%
CAGR, 2024-2029F - 5.7%



Global Saccharin Market Revenue (USD Mn)

CAGR, 2019-2024 - 7.9%
CAGR, 2024-2029F - 8.5%



Source: Industry Report



5 Pharma Intermediates & API

Trends and features of the Pharma Intermediates and APIs Product Category

Key trends in Pharma Intermediates and CDMO market

Increased propensity to outsource manufacturing of intermediates & APIs

- **Enables asset light model** and ability to focus on development of **novel products for venture capital backed start-ups**
- **Provides cost advantages** and **supply chain efficiencies**

De-risking dependence on China by global API and formulations players

- Concerns around specific APIs made in China, accentuated with Covid-19
- China **implemented stricter regulations** and witnessed rising wage costs

Self sufficiency with import substitution

- Government initiatives such as **PLI schemes** and **bulk drug parks**
- Growth driven by **proven skills, educational systems, supply chain reliability, and IP protection**

The growth in the global pharmaceuticals market

- Launch of novel therapies (including biologics and personalized therapies)
- Expansion of existing therapies in several geographies
- Growing demand for generic medicines

Revenue and capacity utilization predictability for the CDMO

- Customers prefers close partnerships with CDMO driven by
  - Confidentiality of the projects
  - Novelty of the underlying chemistry and need for custom-development

Features of a typical arrangement to supply of intermediates to innovators of NCEs

Higher realizations per unit sold

- Key criteria for selection of CDMO include track record in the chemistry and similar therapy areas
- Competitive cost is not the most important consideration

Source: Industry Report

Overview of Blue Jet's Pharma Intermediates and APIs Product Category

Salient features

- Commenced manufacturing pharma intermediates two decades ago, leveraging the customer relationships through high-intensity sweetener business
- Key focus areas include high-value pharma intermediates and APIs
  - In chronic therapeutic areas
  - Import substitution market
- Benefit from collaboration with innovator companies because typical technology transfer reduces the development risk


Client profile

- Innovator pharmaceutical companies and multi-national generic pharmaceutical
- Over 40 customers in India, and 16 globally across Europe, North America, South America, and Asia

Therapeutic areas


- Cardiovascular system ("CVS")
- Oncology
- Central nervous system ("CNS")

Pharma Intermediate and APIs product category performance




CDMO Potential in API for Indian Players


Global CDMO Market by Modality (USD Bn)




Global CDMO Market Revenue (USD Bn)



Global API CDMO Market by Innovation Type (USD Bn)




Indian CDMO Market Revenue (USD Bn)



Source: F&S Report

Cost of R&D and Manufacturing - Comparison of USA versus other regions, 2024



Note: Relative numbers indexed against the USA, based on Industry KOL estimates

Leverage our long-standing customer relationships to continue entering adjacencies in the pharma intermediate and API category

Focus on three niche areas in providing CDMO services

Investigational new drugs and new chemical entities (NCEs)

Develop advanced intermediates for NCEs under trials for US-FDA approvals

Drugs that are still under patent and not genericized

Offering advanced intermediates to innovators for four active pharmaceutical ingredients (APIs) which are still under patent

- Including two APIs in the oncology sector, one API in the cardiovascular system category and one API in the central nervous system category

Genericized drugs that are still niche

Offering multiple advanced intermediates to a number of large generics companies for chronic illness therapies

Blue Jet's positioning

Leverage long-standing relationships with innovator companies

Process research, analytical research and chemistry capabilities

Continuous focus on product quality



6

R&D Capabilities

Our R&D framework

R&D capabilities across

Process research

Portfolio evaluation → **Process development** → **Process scale-up and validation** → **Regulatory filings and approvals**

Analytical research

- Literature search
- Method development and optimization
- Characterization of impurities and standards
- Method validation
- Non-carry over studies
- Stability/hold-time studies

Chemistry research

- Polymorphism screening and optimization
- Pharmaceutical salt screening and optimization
- Cryogenic reactions
- High pressure reactions
- High temperature reactions
- Asymmetric hydrogenation
- Enzymatic transformations
- Particle size distribution studies

Innovative and complex processes

- Catalytic hydrogenation
- Iodination
- Bromination
- Chlorination
- Diazotization
- Esterification
- Hoffman re-arrangement

Sustainability

Various initiatives on energy efficiency, renewable energy, and water conservation to reduce carbon footprint

Invested in windmills with installed capacity of 3.3MW

Created carbon sinks through tree plantations

Focus on enhancing energy efficiency

Effluent treatment plants with modern standards of flocculation, clarification and aeration

Minimizing solvents and using recycled solvents and water





7

Growth Strategy

Our strategies





8

Management and Board of Directors

Experienced and visionary management team backed by independent - Board of Directors

Management team



Akshay Bansarilal Arora
Executive Chairman

- Has more than three decades of experience with the Company
- Holds bachelor's and master's degrees in science from University of Mumbai



Shiven Akshay Arora
Managing Director

- Has more than six years of experience with the Company
- Holds a bachelor's degree in business from Bond University, Gold Coast, Australia



Naresh Suryakant Shah
Executive Director, Head – Marketing

- Has more than three decades of experience in marketing
- Currently also associated as a director of BC Bio Sciences
- Holds a diploma in Chemical Engineering from the Khopoli Polytechnic College, Raigad



Ganesh Karuppannan
Chief Financial Officer

- Previously worked with Philips Electronics, Dr. Reddy's Laboratories, Granules as CFO
- Associate member of Institute of Chartered Accountants of India since 1988



Vimalendu Kumar Singh (V.K. Singh)
Chief Operating Officer

- Previously worked with Strides Pharma, Emcure Pharmaceuticals, RPG Life Sciences, and Ranbaxy Laboratories
- Has a bachelor's degree in chemical engineering from IIT Kanpur and a master's programme from IIFT, New Delhi



Chandrashekar Parenky
President – Research and Development

- Previously worked at Amoli Organics and Kores (India) as CEO
- Holds a doctorate of philosophy in science from the University of Bombay and a master's degree from Birla Institute of Technology & Science

Experienced and visionary management team backed by independent Board of Directors (cont'd)

Management team (cont'd)



Popat B Kedar
Executive Director

- Holds a Bachelor's and Master's degree in Science, specializing in Inorganic Chemistry from Shivaji University, Kolhapur.
- Has over 34 years of experience as a Plant Manager, previously working with Infotech Pharma Pvt. Ltd., Godavari Drugs Pvt. Ltd., and Sara Research Centre.
- Associated with the company since July 2005 and served as a Director at Blue Jet Healthcare Limited from December 31, 2020, to February 1, 2022.



Sweta Poddar
Company Secretary and Compliance Officer

- Has experience of over a decade as a company secretary
- Associated with Chinar Chemicals Private Ltd. and Aarey Drugs and Pharmaceuticals Ltd.
- Holds a bachelors' degree in commerce from the University of Calcutta

Independent board of directors



Girish Paman Vanvari
Independent Director

- Founder and Partner of Transaction Square LLP and Valuation Square LLP . He is the member of Institute of Chartered accountants of India.
- Has experience in tax, regulatory, and business advisory functions
- Holds a bachelor's degree in commerce from Shri Narsee Monjee College of Commerce and Economics
- Other Directorships held: Tarsons Products Ltd , Aurbindo Pharma Ltd , Himadri Specilaity Chemical Ltd, Kolte Patil Developers Ltd



Preeti Gautam Mehta
Independent Director

- Practicing advocate & solicitor and a senior partner of Kanga & Co
- Over 30 years of experience in corporate laws, foreign investments, M&A & PE investments, banking, franchising, and hospitality
- Other Directorships held: Sumitomo Chemicals Ltd, Prpten - E Gov Technlogies Ltd, JCB India Ltd



Divya Sameer Momaya
Independent Director

- Holds a bachelor's degree in commerce from the University of Pune
- Partner of D. S. Momaya & Co. LLP and first director of MMB Advisors Private Limited
- Previously worked with BSE Limited and BSEL Infrastructure Realty Limited
- Other Directorships held: GTPL Hathway Ltd, Motilal Oswal Finacial Services Ltd, Motial Oswal Home Finance ltd



Priyanka Yadav
Independent Director

- Ms. Priyanka Yadav, a Fellow Member of ICSI, holds bachelor's, master's, and law degrees from the University of Mumbai.
- She leads Priyanka Yadav & Associates with 6+ years of experience in corporate laws, NCLT matters, and compliance.
- An expert in listing compliance, IPOs, and corporate restructuring, she advises on governance and legal due diligence.

Thank you!

BLUE JET HEALTHCARE LIMITED

Registered Office
701,702, 7th Floor, Bhumiraj Costarica,
Sector 18, Sanpada, Navi Mumbai Thane
400705, Maharashtra, India

NSE: BLUEJET, **BSE:** 544009
ISIN: INE0KBH01020
Website: www.bluejethealthcare.com

INVESTOR RELATIONS AT

Blue Jet Healthcare Limited
Sanjay Sinha, Deputy Chief Financial Officer
sanjay.sinha@bluejethealthcare.com

EY

Kunal Bhoite
kunal.bhoite@in.ey.com

Advait Bhadekar
advait.bhadekar@in.ey.com